奥利司他降低超重肥胖患者体质量的临床效果及安全性评价  

Clinical effect and safety evaluation of orlistatin reducing body mass of superobese patients

作　　者：魏燕[1] 金剑虹[1] 王雁秋 WEI Yan;JIN Jianhong;WANG Yanqiu(Department of Endocrinology and Metabolism,Hangzhou Hospital of Traditional Chinese Medicine,Hangzhou310007,China)

机构地区：[1]杭州市中医院内分泌代谢科,浙江杭州310007

出　　处：《中国现代医生》2020年第5期114-117,共4页China Modern Doctor

基　　金：浙江省中医药科技计划项目(2019ZA083)。

摘　　要：目的评价奥利司他降低超重肥胖患者体质量的临床效果及安全性。方法选取我院2016年10月~2019年1月收治的原发性肥胖患者94例,采用随机数字表法分为两组。两组患者均给予控制饮食、有氧运动等综合治疗,对照组给予安慰剂治疗,观察组给予奥利司他治疗,均连续治疗12周。分析两组患者治疗后的疗效、安全性及体重、体质量指数(BMI)、体脂百分比、白细胞介素-1β(IL-1β)、脂联素(APN)、哺乳动物雷帕霉素靶蛋白(mTOR)、瘦素(Leptin)的水平变化。结果观察组总有效率(93.62%)高于对照组(78.72%),总不良反应率(10.64%)与对照组(2.13%)比较,差异无统计学意义(P>0.05)。两组治疗前体重、BMI、体脂百分比组间比较,差异无统计学意义(P>0.05)。观察组治疗后体重(68.56±4.01)kg、BMI(25.75±1.43)kg/m2、体脂百分比(30.10±2.42)%低于对照组(P<0.05)。两组治疗前IL-1β、APN、mTOR、Leptin水平组间比较,差异无统计学意义(P>0.05)。观察组治疗后APN水平高于对照组,IL-1β、mTOR、Leptin水平低于对照组(P<0.05)。结论奥利司他可降低超重肥胖患者体质量、BMI、体脂百分比,调节血清APN、IL-1β、mTOR、Leptin的表达水平,且安全性好。Objective To evaluate the clinical effect and safety of orlistat in reducing the body mass of superobese patients.Methods Ninety-four patients with primary obesity treated in our hospital from October 2016 to January 2019 were selected and divided into two groups by the random number method.Comprehensive treatments such as Diet control and aerobics were given to the patients in the two groups,placebo treatment was given to the control group,and orlistat treatment was given to the observation group,which all lasted for 12 weeks.The level changes of effect,safety,body weight,body mass index(BMI),body fat percentage,interleukin-1β(IL-1β),adiponectin(APN),mammalian target of rapamycin(mTOR),and leptin after treatment in the two groups were analyzed.Results It was found that the overall response rate in the observation group(93.62%)was higher than that in the control group(78.72%);there were no statistically significant differences in the overall adverse reaction rate between the observation group(10.64%)and the control group(2.13%)(P>0.05).There were no statistically significant differences in the body weight,BMI or body fat percentage before treatment in the two groups(P>0.05);the body weight[(68.56±4.01)kg],BMI[(25.75±1.43)kg/m2]and the body fat percentage[(30.10±2.42)%]after treatment in the observation group were lower than those in the control group(P<0.05).There were no statistically significant differences in the levels of IL-1β,APN,mTOR or leptin before treatment in the two groups(P>0.05).The APN level after treatment in the observation group was higher than that in the control group,and the levels of IL-1β,mTOR and leptin after treatment in the observation group were lower than those in the control group(P<0.05).Conclusion Orlistat can reduce the body mass,BMI and body fat percentage,and regulate the expression levels of APN,IL-1β,mTOR and leptin in blood serum,which has good safety.

关 键 词：奥利司他 原发性肥胖 体质量指数 脂联素 瘦素 

分 类 号：R589.2[医药卫生—内分泌]